Noncutaneous immune-related adverse events predict overall and progression-free survival in patients with cutaneous toxicities after immune checkpoint inhibitor therapy.
作者信息
Asdourian Maria S, Jacoby Ted V, Shah Nishi, Otto Tracey, Thompson Leah L, Dee Edward Christopher, Reynolds Kerry L, Semenov Yevgeniy R, Chen Steven T
机构信息
Harvard Medical School, Boston, Massachusetts; Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts.
Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts; University of Hawaii at Manoa John A. Burns School of Medicine, Honolulu, Hawaii.
出版信息
J Am Acad Dermatol. 2023 Jun;88(6):1368-1370. doi: 10.1016/j.jaad.2022.12.049. Epub 2023 Feb 2.
Abstract
摘要
相似文献
1
Noncutaneous immune-related adverse events predict overall and progression-free survival in patients with cutaneous toxicities after immune checkpoint inhibitor therapy.非皮肤免疫相关不良事件可预测免疫检查点抑制剂治疗后出现皮肤毒性的患者的总生存期和无进展生存期。
J Am Acad Dermatol. 2023 Jun;88(6):1368-1370. doi: 10.1016/j.jaad.2022.12.049. Epub 2023 Feb 2.
2
Evaluating patterns of co-occurrence between cutaneous and noncutaneous immune-related adverse events after immune checkpoint inhibitor therapy.评估免疫检查点抑制剂治疗后皮肤和非皮肤免疫相关不良事件的共现模式。
J Am Acad Dermatol. 2023 Jan;88(1):246-249. doi: 10.1016/j.jaad.2022.05.015. Epub 2022 May 13.
3
Immune checkpoint inhibitor-related dermatologic adverse events.免疫检查点抑制剂相关的皮肤不良反应。
J Am Acad Dermatol. 2020 Nov;83(5):1255-1268. doi: 10.1016/j.jaad.2020.03.132. Epub 2020 May 23.
4
Cutaneous Toxicities in Lung Cancer Patients on Immune Checkpoint Inhibitor Therapy.免疫检查点抑制剂治疗肺癌患者的皮肤毒性。
Clin Lung Cancer. 2021 May;22(3):195-200.e1. doi: 10.1016/j.cllc.2021.01.006. Epub 2021 Jan 22.
5
Management of immune checkpoint inhibitor-related dermatologic adverse events.免疫检查点抑制剂相关皮肤不良反应的管理。
Thorac Cancer. 2020 Feb;11(2):488-492. doi: 10.1111/1759-7714.13275. Epub 2019 Dec 9.
6
[Cutaneous Toxicity of Immune Checkpoint Inhibitors: A Narrative Review].免疫检查点抑制剂的皮肤毒性：一篇叙述性综述
Acta Med Port. 2020 May 4;33(5):335-343. doi: 10.20344/amp.12424.
7
Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management.免疫检查点抑制剂相关的皮肤免疫不良反应（irAEs）：皮肤科管理视角
J Cutan Med Surg. 2021 Jan-Feb;25(1):59-76. doi: 10.1177/1203475420943260. Epub 2020 Aug 3.
8
Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features.免疫检查点抑制剂治疗的皮肤毒性：组织病理学特征综述。
J Am Acad Dermatol. 2020 Oct;83(4):1130-1143. doi: 10.1016/j.jaad.2020.04.105. Epub 2020 Apr 29.
9
Patterns of Cutaneous and Noncutaneous Immune-Related Adverse Events Among Patients With Advanced Cancer.晚期癌症患者的皮肤和非皮肤免疫相关不良事件模式。
JAMA Dermatol. 2021 May 1;157(5):577-582. doi: 10.1001/jamadermatol.2021.0326.
10
Management of PD-1/PD-L1 blockade immune-related skin toxicities: perspectives and issues.PD-1/PD-L1阻断免疫相关皮肤毒性的管理：观点与问题
Immunotherapy. 2021 Jul;13(10):795-798. doi: 10.2217/imt-2021-0071. Epub 2021 May 6.
本文引用的文献
1
Cutaneous immune-related adverse events among Taiwanese cancer patients receiving immune checkpoint inhibitors link to a survival benefit.台湾癌症患者接受免疫检查点抑制剂治疗后出现的皮肤免疫相关不良反应与生存获益相关。
Sci Rep. 2022 Apr 29;12(1):7021. doi: 10.1038/s41598-022-11128-5.
2
Histologic subtype of cutaneous immune-related adverse events predicts overall survival in patients receiving immune checkpoint inhibitors.皮肤免疫相关不良事件的组织学亚型可预测接受免疫检查点抑制剂治疗患者的总生存期。
J Am Acad Dermatol. 2022 Sep;87(3):651-653. doi: 10.1016/j.jaad.2021.11.050. Epub 2021 Dec 4.
3
Association of Immune Related Adverse Events With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Cancers: A Systemic Review and Meta-analysis.免疫相关不良事件与免疫检查点抑制剂疗效及癌症总生存期的关联：一项系统评价和荟萃分析
Front Oncol. 2021 Apr 12;11:633032. doi: 10.3389/fonc.2021.633032. eCollection 2021.
4
Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.与免疫检查点抑制剂治疗非小细胞肺癌相关的多系统免疫相关不良事件。
JAMA Oncol. 2020 Dec 1;6(12):1952-1956. doi: 10.1001/jamaoncol.2020.5012.
5
Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study.PD-1/PD-L1抑制剂治疗后皮炎的特征及其与多种肿瘤学结局的关联：一项回顾性病例对照研究。
J Am Acad Dermatol. 2018 Dec;79(6):1047-1052. doi: 10.1016/j.jaad.2018.05.035. Epub 2018 May 29.
Zotero 插件